Physician profile
Jonathan Lance Babin
NPI 1528329950
$7,295.42
in general payments reported to CMS, 2019-2025
10 companies · $67.82 in 2025
The $67.82 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,338 · 2020: $724 · 2021: $33.91 · 2022: $105 · 2023: $85.53 · 2024: $941 · 2025: $67.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $816 · Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $815.52 |
| Food and Beverage | $279.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,814.75 | 2019-2024 | |
| Baxter Healthcare | $86.43 | 2019 | |
| Allergan, INC. | $75.28 | 2020-2021 | |
| La Jolla Pharmaceutical Company | $73.92 | 2019-2023 | Giapreza |
| Davol INC. | $53.73 | 2022 | |
| Becton, Dickinson and Company | $53.11 | 2023 | Phasix Mesh |
| Conmed Corporation | $50.78 | 2022 | |
| Acera Surgical, INC. | $40.00 | 2025 | Restrata Wound Matrix |
| Medtronic, INC. | $27.82 | 2025 | Transorb |
| Zimmer Biomet Holdings, INC. | $19.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Babin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.